HA
CRBU icon

Herold Advisors’s Caribou Biosciences CRBU Stock Holding History

Herold Advisors’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,750
Closed -$16.1K – 279
2022
Q1 		$16.1K Buy
+1,750
New +$18.4K 0.01% 542
2021
Q4 		– Sell
-2,550
Closed -$60K – 280
2021
Q3 		$60K Buy
+2,550
New +$62.3K 0.02% 345

Other funds holding CRBU

PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Herold Advisors's CRBU Position: Q2 2022 in Review

Herold Advisors sold out of Caribou Biosciences (CRBU) in Q2 2022, closing a stake of 1,750 shares — an estimated $16.1K sold.

Herold Advisors first reported a position in CRBU in Q3 2021 and held it in 2 quarters. The position peaked at $60K in Q3 2021. 120 funds tracked by Wall St. Rank hold CRBU as of Q2 2022.

  • Herold Advisors reported no remaining Caribou Biosciences position as of Q2 2022 after selling out during the quarter.
  • Herold Advisors sold 1,750 Caribou Biosciences shares in Q2 2022, an estimated $16.1K.
  • Herold Advisors first reported a position in Caribou Biosciences in Q3 2021 and held it in 2 quarters.
  • Herold Advisors's Caribou Biosciences position peaked at $60K in Q3 2021.
  • 120 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2022.

Based on Herold Advisors's 13F filing for Q2 2022, filed 15 Jul 2022.